- Policy
- Rep. Young-hee Choi ‘expenses surged after Moon Care’
- by Lee, Tak-Sun Oct 18, 2023 05:49am
- After the implementation of Moon Jae-in Care, which was implemented to strengthen health insurance coverage, KRW 5.272 trillion was found to have been spent on drugs for seriously ill patients over the 6 years and exceeded the expenditure target every year. According to data Rep. Choi Young-hee (People Power Party, proportional representa
- Policy
- Layla+Celecoxib coming soon
- by Lee, Tak-Sun Oct 18, 2023 05:48am
- A compound that combines different osteoarthritis treatments based on natural products and synthesis is expected to be released on the 1st of next month. 20 companies are selling their products, and it is noteworthy whether it will create a new wind in the osteoarthritis treatment market. The original drug ingredient of Danggui, Mogwa, Bangp
- Policy
- Pharma-Bio Control Tower launched…first meeting next month
- by Lee, Jeong-Hwan Oct 18, 2023 05:48am
- A presidential order to establish the Biohealth Innovation Committee, a control tower to foster the pharmaceutical bio-industry, has been issued. The government plans to hold its first meeting next month to begin discussing major agendas. With the launch of a pan-ministerial organization, financial and administrative support is expected to be
- Policy
- Daewoong's new diabetes drug 'Envlo',
- by Lee, Tak-Sun Oct 17, 2023 05:28am
- Envlo, a new diabetes drug developed by Daewoong Pharmaceutical, is entering long-term safety and efficacy testing of the Zemiglo three-drug therapy. While triple therapy of the Metformin+SGLT2i+DPP4i has been approved for reimbursement since last April, Daewoong Pharmaceutical is expected to establish its position as a latecomer, Envlo, in
- Policy
- Yuhan’s Leclaza passes DREC review for 1st-line NSCLC
- by Lee, Tak-Sun Oct 16, 2023 05:24am
- Yuhan Corp’s application to extend coverage for its 3rd-generation EGFR TKI non-small-cell lung cancer treatment Leclaza (lasertinib)' as a first-line treatment is making rapid progress. After passing the Health Insurance Review and Assessment Service review, all that remains is drug price negotiations with the National Health Insurance
- Policy
- Regkirona approval is for the Moon care to build up records
- by Lee, Jeong-Hwan Oct 13, 2023 05:30am
- People Power Party lawmaker Lee Jong-seong pointed out the Moon Jae-in government's budget support for Celltrion's COVID-19 treatment Regkirona as a problem. Rep. Lee Jong-seong criticized the approval of Regkirona, saying it lacked proper verification of effectiveness in order to build on the previous government's legacy of the K vaccine. O
- Policy
- NA Rep Kang ‘Increase gov't support to treat breast cancer'
- by Lee, Jeong-Hwan Oct 13, 2023 05:29am
- It has been pointed out that the government should strengthen economic support for innovative new drugs that treat severe diseases to improve the treatment rate of breast cancer patients. The number of female cancer patients is significantly higher than that of male cancer patients in the same age group, and the number of breast cancer
- Policy
- The fate of the drugs identified in the inspeciton inspectio
- by Lee, Tak-Sun Oct 13, 2023 05:29am
- Specifically, they are breast cancer treatment Enhertu, Parkinson's disease treatment Madopar, and other immunotherapy drugs. Enhertu was mentioned by People Power Party lawmaker Kang Ki-yoon. He said that the number of female cancer patients is rapidly increasing and ordered coverage of expensive innovative treatments. At this point, Enh
- Policy
- Reimb extensions for Keytruda to be rediscussed later
- by Lee, Tak-Sun Oct 13, 2023 05:29am
- MSD Korea's immunotherapy drug 'Keytruda (pembrolizumab)', which applied for a large-scale reimbursement extension, was unable to pass the first hurdle and was determined in need of rediscussions. The authorities plan to first receive the pharmaceutical company's financial sharing plan and then decide whether to set a reimbursement stand
- Policy
- Overseas drug price comparison plan to be announced
- by Lee, Tak-Sun Oct 12, 2023 05:37am
- The final plan will likely be finalized after gathering opinions from the pharmaceutical industry. It is expected that a plan to reevaluate overseas drug prices will be revealed around the end of the year. Health authorities plan to prepare a reevaluation plan by the end of the year and then proceed with it starting next year. According to t
